PharmSource – Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars – 2018 Edition
- Pages: 77
- Published: December 2018
- Report Code: GDPS0023MAR
Biosimilars are drugs that are highly similar but not identical to branded “innovator” biologics: large molecule, immunogenic drugs produced from living cells. “Innovator” biologics are the first to be approved, and when their patent protection expires, biosimilars may be approved, in a similar way to small molecule branded drugs and their generics.
There are no clinically meaningful differences in quality, safety and efficacy between biosimilars and innovator biologics. The exact definition of a biosimilar varies by regulator.
Biosimilars bring competition to expensive innovator biologics and represent a cost-saving option for payers.
More than 50 biosimilars are approved in the EU, while the FDA lags behind with 17 approvals but is catching up fast. As more innovator biologics come off-patent in the near future, this will bring a huge opportunity for biosimilar companies and for biosimilar manufacturers.
Key Questions Answered
What biosimilars are marketed in the US and EU?
How is biosimilar manufacturing and packaging outsourced?
What therapies are in the biosimilar pipeline?
In what regions is biosimilar development concentrated?
How does biosimilar manufacturing differ by molecule type?
When will innovator biologic patents expire, allowing biosimilar development?
What proportion of biosimilar manufacturing is kept in-house?
How will contract analytical testing services be affected by the rise of biosimilars?
Detailed view from the GlobalData Pharma Intelligence Center Drugs Database and Regulatory Milestones Tracker Database:
• marketed innovator biologics
• marketed biosimilars
• innovator biologic patent expiries and waves of biosimilar opportunity
• biosimilar clinical pipeline
Detailed view from the GlobalData PharmSource Contract Service Providers database:
• existing CDMO contracts for biosimilars for API, dose and packaging
Reasons to buy
The report will enable you to:
To describe and evaluate the biosimilar market opportunity for CDMOs and CMOs
To describe the network of CDMOs that currently manufacture for the biosimilar market
To assess the outlook for buyers and sellers of contract manufacturing services for biosimilars, including factors influencing client decisions about whether to manufacture in-house or outsource
Advanced Accelerator Applications
Beijing Fogangren Bio-Pharm Tech
Table of Contents
1. Executive Summary 4
2. Introduction 6
3. The Biosimilar Opportunity 7
4. Approved Biosimilars 10
5. Market Penetration 29
Regional Variability in Biosimilar Uptake 32
Biosimilar vs. Innovator Market Share 34
New Patient Access 35
6. The Biosimilar Pipeline 36
7. Sourcing Arrangements for Biosimilars 42
Joint Ventures 48
Capacity and scale 52
API Segmentation 52
Geography and Partnerships 53
Analytic and Testing CDMOs 54
8. Notes on Methodology 56
9. Appendix 57
9.1 Bibliography 57
9.2 Primary Research – Key Opinion Leaders in this Report 58
9.3 Additional Tables 59
9.4 About the Authors 75
List of Tables
Table 1: FDA-Approved Biosimilars and Their API Manufacturing Contracts 11
Table 2: FDA-Approved Biosimilars and Their Dose Manufacturing Contracts 13
Table 3: FDA-Approved Biosimilars and Their Packaging Contracts 15
Table 4: EMA-Approved Biosimilars and Their API Manufacturing Contracts 17
Table 5: EMA-Approved Biosimilars and Their Dose Manufacturing Contracts 21
Table 6: EMA-Approved Biosimilars and Their Packaging Contracts 25
Table 7: Waves of Biosimilar Opportunity by EU Patent Expiry of Biologic Innovators 59
Table 8: Waves of Biosimilar Opportunity by US Patent Expiry of Biologic Innovators 67
List of Figures
Figure 1: Waves of Biosimilar Opportunity by EU Patent Expiry of Innovator Biologics 8
Figure 2: Market Share Forecast by Class for UC in the US, 2016 30
Figure 3: Biosimilars in Clinical Development 37
Figure 4: Biosimilar Clinical Development by Sponsor Type 39
Figure 5: Biosimilar Clinical Development by Sponsor HQ Location 40
Figure 6: Outsourcing of Biosimilar Approvals, EU 43
Figure 7: Proportion of API Outsourcing of Biosimilar Approvals, EU, Jan. 2009–Dec. 2018 44
Figure 8: Proportion of Dose Outsourcing of Biosimilar Approvals, EU, Jan. 2009–Dec. 2018 44
Figure 9: Outsourcing of Biosimilar Approvals, US 46
Figure 10: Proportion of API Outsourcing of Biosimilar Approvals, US 46
Figure 11: Proportion of Dose Outsourcing of Biosimilar Approvals, US 47
Figure 12: Manufacturing of FDA- and EMA-Approved Biosimilars by Molecule Type 50